End of the line for cannabinoid receptor 1 as an anti-obesity _target? A wave of terminations of development programmes for cannabinoid receptor 1 blockers for …
D Jones - Nature Reviews Drug Discovery, 2008 - go.gale.com
In October this year, the European Medicines Agency recommended suspending sales of
Sanofi-Aventis's anti-obesity agent rimonabant (Acomplia)--which has been approved in
Europe for 2 years but has not been approved in the US--concluding that the benefits of
rimonabant no longer outweigh its risks. The agency considered that experience with
rimonabant since approval has indicated that serious psychiatric disorders may be more
common than in the clinical trials used in the initial assessment of the medicine. Sanofi …
Sanofi-Aventis's anti-obesity agent rimonabant (Acomplia)--which has been approved in
Europe for 2 years but has not been approved in the US--concluding that the benefits of
rimonabant no longer outweigh its risks. The agency considered that experience with
rimonabant since approval has indicated that serious psychiatric disorders may be more
common than in the clinical trials used in the initial assessment of the medicine. Sanofi …